1. Home
  2. ZTEK vs BDSX Comparison

ZTEK vs BDSX Comparison

Compare ZTEK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentek Ltd.

ZTEK

Zentek Ltd.

HOLD

Current Price

$0.67

Market Cap

78.2M

Sector

Industrials

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$12.09

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZTEK
BDSX
Founded
2008
2005
Country
Employees
N/A
N/A
Industry
Major Chemicals
Precision Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.2M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZTEK
BDSX
Price
$0.67
$12.09
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
70.2K
262.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$22.01
Revenue Next Year
N/A
$26.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$3.44
52 Week High
$1.84
$20.40

Technical Indicators

Market Signals
Indicator
ZTEK
BDSX
Relative Strength Index (RSI) 38.88 67.15
Support Level $0.62 $9.83
Resistance Level $0.69 $13.63
Average True Range (ATR) 0.07 1.37
MACD -0.01 0.08
Stochastic Oscillator 17.10 79.75

Price Performance

Historical Comparison
ZTEK
BDSX

About ZTEK Zentek Ltd.

Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: